Versanis Bio

Versanis Bio is a clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The company’s lead asset, bimagrumab, is being advanced in a Phase 2b study as a novel treatment for obesity to help adults achieve and maintain both substantial fat loss and a healthy body composition, with additional indications to follow.

Headquarters New York, NY
Pipeline Status Phase 2b
Twitter @VersanisBio
LinkedIn Versanis Bio